Drug Profile
Research programme: Alzheimer's disease immunotherapeutics - SciSparc
Latest Information Update: 10 Feb 2021
Price :
$50
*
At a glance
- Originator NasVax
- Developer SciSparc
- Class Alzheimer vaccines; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Jan 2021 Therapix Biosciences is now called SciSparc
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Israel
- 13 Jan 2014 Therapix Biosciences responds to a letter from Ramot at Tel-Aviv University related to the licensing agreement for the BBS technology